INTRODUCTION: In 2014, a reflexive screening protocol for Lynch syndrome (LS) via an immunohistochemistry (IHC) assay was shown to be cost-effective; however, the screening rates at a predominant Hispanic-rich institution are unclear. We hypothesized that implementation of a universal tumor screening (UTS) protocol requiring screening for LS via IHC in patients with newly diagnosed colorectal cancer (CRC) at our Hispanic-rich institution would improve detection of LS by increasing screening rates. METHODS AND MATERIALS: This is a retrospective analysis of screening rates of 3 sequential cohorts of newly diagnosed patients with CRC between January 2012 and April 2016 at the University Health System and with follow-up at National Cancer Institute-designated Mays Cancer Center at University of Texas Health San Antonio. Cohort 1 consisted of patients screened using old screening guidelines (PRE). Cohort 2 consisted of patients screened when treating clinicians were receiving education on the new protocol (PERI). Cohort 3 consisted of patients screened after implementation of the UTS protocol (POST). RESULTS: The majority of 312 patients were Hispanic (62.5%), 18.1% were < 50 years, and 81.9% were ≥ 50 years of age (median age, 57 years). Of patients with CRC screened for LS via IHC, the PRE, PERI, and POST cohorts had screening rates of 31%, 64%, and 58%, respectively. We found significant differences when comparing the PRE with POST sequential cohorts (P < .01). CONCLUSION: The quality of Lynch syndrome-related family histories and screening rates were significantly improved after implementation in our Hispanic-rich population. Future studies are warranted to provide insight into clinical effects of increased screening, provider and patient surveillance, and screening-related systemic barriers.
INTRODUCTION: In 2014, a reflexive screening protocol for Lynch syndrome (LS) via an immunohistochemistry (IHC) assay was shown to be cost-effective; however, the screening rates at a predominant Hispanic-rich institution are unclear. We hypothesized that implementation of a universal tumor screening (UTS) protocol requiring screening for LS via IHC in patients with newly diagnosed colorectal cancer (CRC) at our Hispanic-rich institution would improve detection of LS by increasing screening rates. METHODS AND MATERIALS: This is a retrospective analysis of screening rates of 3 sequential cohorts of newly diagnosed patients with CRC between January 2012 and April 2016 at the University Health System and with follow-up at National Cancer Institute-designated Mays Cancer Center at University of Texas Health San Antonio. Cohort 1 consisted of patients screened using old screening guidelines (PRE). Cohort 2 consisted of patients screened when treating clinicians were receiving education on the new protocol (PERI). Cohort 3 consisted of patients screened after implementation of the UTS protocol (POST). RESULTS: The majority of 312 patients were Hispanic (62.5%), 18.1% were < 50 years, and 81.9% were ≥ 50 years of age (median age, 57 years). Of patients with CRC screened for LS via IHC, the PRE, PERI, and POST cohorts had screening rates of 31%, 64%, and 58%, respectively. We found significant differences when comparing the PRE with POST sequential cohorts (P < .01). CONCLUSION: The quality of Lynch syndrome-related family histories and screening rates were significantly improved after implementation in our Hispanic-rich population. Future studies are warranted to provide insight into clinical effects of increased screening, provider and patient surveillance, and screening-related systemic barriers.
Authors: Laura C Beamer; Marcia L Grant; Carin R Espenschied; Kathleen R Blazer; Heather L Hampel; Jeffrey N Weitzel; Deborah J MacDonald Journal: J Clin Oncol Date: 2012-02-21 Impact factor: 44.544
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Leticia Moreira; Francesc Balaguer; Noralane Lindor; Albert de la Chapelle; Heather Hampel; Lauri A Aaltonen; John L Hopper; Loic Le Marchand; Steven Gallinger; Polly A Newcomb; Robert Haile; Stephen N Thibodeau; Shanaka Gunawardena; Mark A Jenkins; Daniel D Buchanan; John D Potter; John A Baron; Dennis J Ahnen; Victor Moreno; Montserrat Andreu; Maurizio Ponz de Leon; Anil K Rustgi; Antoni Castells Journal: JAMA Date: 2012-10-17 Impact factor: 56.272
Authors: M B Loughrey; P M Waring; A Tan; M Trivett; S Kovalenko; V Beshay; M-A Young; G McArthur; A Boussioutas; A Dobrovic Journal: Fam Cancer Date: 2007-04-24 Impact factor: 2.375
Authors: Glenn E Palomaki; Monica R McClain; Stephanie Melillo; Heather L Hampel; Stephen N Thibodeau Journal: Genet Med Date: 2009-01 Impact factor: 8.822
Authors: Deanna S Cross; Alanna Kulchak Rahm; Tia L Kauffman; Jennifer Webster; Anh Quynh Le; Heather Spencer Feigelson; Gwen Alexander; Paul Meier; Adedayo A Onitilo; Pamala A Pawloski; Andrew E Williams; Stacey Honda; Yeehwa Daida; Catherine A McCarty; Katrina A B Goddard Journal: Genet Med Date: 2013-05-02 Impact factor: 8.822
Authors: Mark R Kilgore; Carrie A McIlwain; Rodney A Schmidt; Barbara M Norquist; Elizabeth M Swisher; Rochelle L Garcia; Mara H Rendi Journal: J Pathol Inform Date: 2016-11-29
Authors: Deborah Cragun; Rita D DeBate; Susan T Vadaparampil; Julie Baldwin; Heather Hampel; Tuya Pal Journal: Genet Med Date: 2014-03-20 Impact factor: 8.822